Klinische Studien zum malignen Melanom
Inhaltsübersicht
Kontaktdaten für Klinische Studien
Für Studienanfragen steht Ihnen unser Dermato-Onkologisches Team zur Verfügung.
Tel.-Nr.: 0621-383-4450 oder 0621-383-3905
e-mail: dermato.onkologie@umm.de
Klinische Studien mit möglichem Studieneinschluss
- MSD MK-3475
Randomized, Phase II study of the PD-1 inhibitor MK-3475 versus chemotherapy in patients with advanced melanoma
- GSK BRF115532 - COMBI-AD
Randomisierte, doppelblinde Phase III-Studie zur Dabrafenib in Kombination mit Trametinib im Vergleich zu zwei Placebos bei der adjuvanten Behandlung des Hochrisiko-Melanoms mit BRAF-V600-Mutation nach chirurgischer Resektion
- Roche GO28141 co-BRIM
A Phase III, double-blind, placebo-controlled study of vemurafenib + placebo versus vemurafenib in combination with GDC-0973 (MEK-inhibitor) in previously untreated BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma
- Roche GO27826
A Phase III, randomized, double blind, placebo-controlled study of vemurafenib (RO5185426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence
- BMS IMAGE
A multi-national, prospective, observational study in patients with unresectable or metastatic melanoma
- ROCHE ZESS
A prospective safety study of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib.
- AB Science AB08026
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit
- ADO - Sentinel Studie
Kontrollierte und prospektiv randomisierte Therapiestudie zum Vergleich einer radikalen Lymphadenektomie versus Beobachtung bei Patienten mit malignem Melanom >1,0 mm Tumordicke und positivem Wächter-Lymphknoten
Klinische Studien aktuell kein Studieneinschluss mehr möglich
GSK MEK116513 - COMBI-v
A Phase III, randomisied, open-label study comparing the combination of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, to the BRAF inhibitor venmurafenib in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma
GSK PRAME
An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with PRAME-positive metastatic melanoma
ROCHE BRAIN-METS
An open-label, single-arm phase II, multicenter study to evaluate the efficacy of Vemurafenib in patients with brain metastases.
GSK MEK115306 - COMBI-d
Randomisierte, doppelblinde Studie der Phase III zum Vergleich der Kombination des BRAF-Hemmers Dabrafenib und des MEK-Hemmers Trametinib mit Dabrafenib und Placebo als First-Line-Therapie bei Patienten mit nicht reserzierbarem (Stadium IIIC) oder metastasiertem (Stadium IV) kutanen Melanom mit BRAF-V600E/K-Mutation
GSK MEK114267
A phase III randomized, open-label study comparing GSK1121212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma
DeCOG-MM-PAL11
The IPI - Multibasket Trial in advanced uveal melanoma: Prospective clinical phase II multibasket study in Melanoma patients with advanced disease
ADO ChemoSensMM
Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma
ROCHE MO25515 An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma
BMS CA 184-029
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase III trial of the EORTC Melanoma Group
GSK Predict
Predictive gene signature fore REsponse to recMAGE-A3 in unresecteD metastatIc CuTaneous melanoma Recombinant MAGE-A3 protein (recMAGE-A3) combined with the AS15 immunological Adjuvant System
GSK Derma
A double-blind, randomized, placebo-controlled phase III study to assiss the efficacy of recMAGE-A3+AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
BMS CA 184-025
a multicenter, open-label, phase II study of Ipilimumab (MDX-010) extended-treatment Monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols
BMS CA 184-024
a multicenter, randomized, double-blind, two-arm, phase III Study in Patients with untreated stage III (unresectable) or IV Melanoma receiving Dacarbazine plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine with placebo
